Mullis v. Janssen Pharmaceuticals, Inc.
This text of Mullis v. Janssen Pharmaceuticals, Inc. (Mullis v. Janssen Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
1 OPY UNITED STATES JUDICIAL PANEL Tat on ; ‘ MULTIDISTRICT LITIGATION
IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION MDL No. 2750
(SEE ATTACHED SCHEDULE)
CONDITIONAL TRANSFER ORDER (CTO —41)
On December 7, 2016, the Panel transferred 18 civil action(s) to the United States District Court for the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See 223 F.Supp.3d 1345 (J.P.M.L. 2016). Since that time, 137 additional action(s) have been transferred to the District of New Jersey. With the consent of that court, all such actions have been assigned to the Honorable Brian R. Martinotti. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of New Jersey and assigned to Judge Martinotti. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the District of New Jersey for the reasons stated in the order of December 7, 2016, and, with the consent of that court, assigned to the Honorable Brian R. Martinotti. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel. Inasmuch as no objection is pending at this time, the stay is lifted. FOR THE PANEL: aL = Zz. 4 John W. Nichols Clerk of the Panel
IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION MDL No. 2750
SCHEDULE CTO-—41 — TAG—ALONG ACTIONS
DIST DIV. C.A.NO. CASE CAPTION
GEORGIA SOUTHERN GAS 4 20-00130 Mullis et al v. Janssen Pharmaceuticals, Inc. et al
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
Mullis v. Janssen Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/mullis-v-janssen-pharmaceuticals-inc-gasd-2020.